JP7729713B2 - 肺炎症を低減させる方法 - Google Patents

肺炎症を低減させる方法

Info

Publication number
JP7729713B2
JP7729713B2 JP2019571349A JP2019571349A JP7729713B2 JP 7729713 B2 JP7729713 B2 JP 7729713B2 JP 2019571349 A JP2019571349 A JP 2019571349A JP 2019571349 A JP2019571349 A JP 2019571349A JP 7729713 B2 JP7729713 B2 JP 7729713B2
Authority
JP
Japan
Prior art keywords
chelating agent
dose
day
inflammation
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019571349A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524173A (ja
Inventor
クレメンツ，バリー
Original Assignee
レスピリオン・ファーマシューティカルズ・プロプライエタリー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902365A external-priority patent/AU2017902365A0/en
Application filed by レスピリオン・ファーマシューティカルズ・プロプライエタリー・リミテッド filed Critical レスピリオン・ファーマシューティカルズ・プロプライエタリー・リミテッド
Publication of JP2020524173A publication Critical patent/JP2020524173A/ja
Priority to JP2023035901A priority Critical patent/JP7848150B2/ja
Priority to JP2025031885A priority patent/JP2025098035A/ja
Application granted granted Critical
Publication of JP7729713B2 publication Critical patent/JP7729713B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019571349A 2017-06-20 2018-06-20 肺炎症を低減させる方法 Active JP7729713B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023035901A JP7848150B2 (ja) 2017-06-20 2023-03-08 肺炎症を低減させる方法
JP2025031885A JP2025098035A (ja) 2017-06-20 2025-02-28 肺炎症を低減させる方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017902365 2017-06-20
AU2017902365A AU2017902365A0 (en) 2017-06-20 Method For Reducing Lung Inflammation
PCT/AU2018/050609 WO2018232452A1 (en) 2017-06-20 2018-06-20 METHOD FOR REDUCING PULMONARY INFLAMMATION

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2023035901A Division JP7848150B2 (ja) 2017-06-20 2023-03-08 肺炎症を低減させる方法
JP2025031885A Division JP2025098035A (ja) 2017-06-20 2025-02-28 肺炎症を低減させる方法

Publications (2)

Publication Number Publication Date
JP2020524173A JP2020524173A (ja) 2020-08-13
JP7729713B2 true JP7729713B2 (ja) 2025-08-26

Family

ID=64735378

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019571349A Active JP7729713B2 (ja) 2017-06-20 2018-06-20 肺炎症を低減させる方法
JP2023035901A Active JP7848150B2 (ja) 2017-06-20 2023-03-08 肺炎症を低減させる方法
JP2025031885A Withdrawn JP2025098035A (ja) 2017-06-20 2025-02-28 肺炎症を低減させる方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023035901A Active JP7848150B2 (ja) 2017-06-20 2023-03-08 肺炎症を低減させる方法
JP2025031885A Withdrawn JP2025098035A (ja) 2017-06-20 2025-02-28 肺炎症を低減させる方法

Country Status (8)

Country Link
US (2) US11491126B2 (https=)
EP (1) EP3641749A4 (https=)
JP (3) JP7729713B2 (https=)
CN (1) CN111050762A (https=)
AU (2) AU2018286649B2 (https=)
BR (1) BR112019027257A2 (https=)
CA (1) CA3067857A1 (https=)
WO (1) WO2018232452A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI818601B (zh) * 2021-10-29 2023-10-11 原創生醫股份有限公司 用於上呼吸道給藥之組成物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
WO2008137747A1 (en) 2007-05-02 2008-11-13 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
AU2016228976B2 (en) * 2015-03-11 2018-11-08 University Of Cincinnati Compositions and methods for treating bacterial infection
EP3383415B1 (en) * 2015-12-01 2021-03-31 Cornell University Use of mitochondrial iron chelators for treatment of chronic obstructive pulmonary disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Aali, M. et al., Iron chelation as novel treatment for lung inflammation in cystic fibrosis, Medical Hypotheses, 2017年05月27日, 発行日, Vol.104, p.86-88
Ｂｒｏｗｎ Ｊ． ｅｔ ａｌ．, ＡＪＤＣ, 1985, 発行日, Ｖｏｌ．１３９, ｐ．８３６－８３９
Ｓｏｐｈｉｅ Ｍｏｒｅａｕ－Ｍａｒｑｕｉｓ ｅｔ ａｌ．，, Ａｍｅｒｉｃａｎ Ｊｏｕｒｎａｌ ｏｆ Ｒｅｓｐｉｒａｔｏｒｙ Ｃｅｌｌ Ａｎｄ Ｍｏｌｅｃｕｌａｒ, 2009, 発行日, Ｖｏｌ.４１, ｐ．３０５－３１３

Also Published As

Publication number Publication date
AU2023270302A1 (en) 2023-12-14
EP3641749A4 (en) 2021-03-17
AU2023270302B2 (en) 2025-10-23
AU2018286649B2 (en) 2023-11-09
US20200163920A1 (en) 2020-05-28
CA3067857A1 (en) 2018-12-27
JP2025098035A (ja) 2025-07-01
JP2020524173A (ja) 2020-08-13
BR112019027257A2 (pt) 2020-07-14
JP2023071952A (ja) 2023-05-23
WO2018232452A1 (en) 2018-12-27
JP7848150B2 (ja) 2026-04-20
AU2018286649A1 (en) 2019-12-05
US11491126B2 (en) 2022-11-08
EP3641749A1 (en) 2020-04-29
US20230045633A1 (en) 2023-02-09
CN111050762A (zh) 2020-04-21

Similar Documents

Publication Publication Date Title
Cantin et al. Aerosolized prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection
Chang et al. Phage therapy for respiratory infections
JP7642033B2 (ja) 肺感染症を低減させる方法
KR101735123B1 (ko) 리포솜 아미카신 제형물로의 폐 장애 치료 방법
US20120058198A1 (en) Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
WO2009055571A2 (en) Methods of treating pulmonary disorders using liposomal vancomycin formulations
JP4745340B2 (ja) 細菌性呼吸器感染症を治療するためのエーロゾル化されたホスホマイシン／アミノグリコシド組合せ
JP2025098035A (ja) 肺炎症を低減させる方法
Stockmann et al. Clinical pharmacokinetics of inhaled antimicrobials
KR20140025534A (ko) 아미카신과 포스포마이신 조합물의 제형 및 인공호흡기 관련 폐렴(vap)과 인공호흡기 관련 기도(vat) 기관지염의 치료 방법 및 시스템
Krishna et al. Liposomal drug delivery to the lungs: a post covid-19 scenario
Sheikh et al. Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment?
US7012091B1 (en) Inhalable inhibitors of inflammation in the respiratory tract
BR122025016291A2 (pt) Uso do agente quelante ácido etilenodiamino tetra-acético (edta) na fabricação de uma formulação inalável, formulação inalável e kit para tratar ou prevenir inflamação no pulmão
Hasan et al. Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics
JP2005504095A (ja) モノバクタム組成物およびその使用方法
US20170020838A1 (en) Treatment for respiratory disease
WO2021205074A1 (en) Inhalable formulation
JP2022514146A (ja) 肺の炎症および線維症を予防または治療する方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230308

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230308

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230322

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230417

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230418

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230519

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250814

R150 Certificate of patent or registration of utility model

Ref document number: 7729713

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150